Mprila Tablet

About

Mprila Tablet contains Apremilast, an innovative oral small-molecule inhibitor of phosphodiesterase 4 (PDE4). By selectively inhibiting PDE4, Apremilast leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. This elevation of cAMP subsequently modulates the expression of various pro-inflammatory and anti-inflammatory mediators, including TNF-alpha, IL-23, and IL-10. The net effect is a reduction in systemic inflammation, which is crucial in the pathogenesis of several immune-mediated inflammatory diseases. It is primarily indicated for the treatment of active psoriatic arthritis, providing relief from joint pain and swelling. Additionally, it is used for moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy, helping to clear skin lesions. Mprila is also effective in treating oral ulcers associated with Behçet's disease, offering a targeted approach to manage these debilitating conditions.

Uses

• Active psoriatic arthritis
• Moderate to severe plaque psoriasis
• Oral ulcers associated with Behçet's disease
• When other systemic therapies are unsuitable

Directions For Use

Take orally twice daily, with or without food, as directed by your physician.

Benefits

• Reduces joint pain and swelling in psoriatic arthritis.
• Clears skin lesions in plaque psoriasis.
• Reduces frequency and severity of oral ulcers in Behçet's.
• Oral administration, avoiding injections.
• Well-tolerated with a favorable safety profile.
• Does not require routine laboratory monitoring.

Side Effects

• Diarrhea
• Nausea
• Upper respiratory tract infections
• Headache
• Abdominal pain
• Vomiting
• Weight decrease
• Insomnia
• Depression (rare, but monitor)
• Migraine
• Back pain
• Fatigue

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may exacerbate gastrointestinal side effects.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus; consult a doctor.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if it is excreted in human milk.
• Liver - No specific dose adjustment required for hepatic impairment.
• Kidney - Dose adjustment is recommended for patients with severe renal impairment.
• Lung - No specific lung-related safety concerns; generally considered safe for patients with lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.